VENMAX
DRUGS AND PHARMACEUTICALS LIMITED.

October 26, 2026

To
The Manager – Listing Department
Bombay Stock Exchange Limited
PJ Towers, Dalal Street
Mumbai – 400001

Scrip Name: VENMAX

Scrip Code: 531015

Sub: Submission of Scrutinizer's Report and E-Voting Results on the National Company Law Tribunal ("NCLT") convened Meeting of the Equity Shareholders of Venmax Drugs and Pharmaceuticals Limited (the "Company") held on October 24, 2026.

Dear Sir/ Madam,

In furtherance to our earlier intimation dated 8th September, 2026, regarding the Scheme of Amalgamation of between Hatri Pharma Private Limited ("Transferor Company") and Venmax Drugs and Pharmaceuticals Limited ("Transferee Company") and their respective Shareholders under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 read with Rules made thereunder ("Scheme"), the Scrutinizer Report and E-Voting Results for the meetings of Equity Shareholders held on October 24, 2026 issued by Ms. Kruthi Kalaga, Scrutinizer (appointed by Hon'ble NCLT, Hyderabad Bench – II) enclosed herewith.

Kindly take the same on record.

Thanking You

Yours Faithfully

For Venmax Drugs and Pharmaceuticals Limited

Priyanka Agarwal
Digitally signed by Priyanka Agarwal
Date: 2026.10.26 18:57:04 +05'30'

Priyanka Agarwal
Company Secretary & Compliance Officer

KRUTHI KALAGA
Advocate
1-3-183/40/68/C/2, Gandhi Nagar Road, SBI Colony, Hyderabad, Telangana 500080
E-mail: kruthikalaga@gmail.com

CONSOLIDATED SCRUTINIZER'S REPORT

[Pursuant to Sections 230 to 232 and Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016, Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023, and the Order dated September 7, 2026 passed by the Hon'ble National Company Law Tribunal, Hyderabad Bench-II in CA (CAA) No. 30/230/HDB/2026]

Date: October 24, 2026

To,
Ms. Sarvani Desiraju, Advocate
Chairperson appointed by the Hon'ble NCLT for the Meeting of the Equity Shareholders of
Venmax Drugs and Pharmaceuticals Limited
CIN: L24230TG1988PLC009102
Sy. No. 115, Brig Sayeed Road, Hanumanji Colony,
Bowenpally, Picket, Hyderabad, Secunderabad, Telangana – 500009

Dear Madam,

Sub: Consolidated Scrutinizer's Report on the results of remote e-voting and e-voting at the Meeting of the Equity Shareholders of Venmax Drugs and Pharmaceuticals Limited convened pursuant to the Order of the Hon'ble National Company Law Tribunal, Hyderabad Bench-II, held on Saturday, October 24, 2026 at 12:30 P.M. (IST) through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM").

1) I, Kruthi Kalaga, was appointed as the Scrutinizer by the Hon'ble National Company Law Tribunal, Hyderabad Bench-II ("NCLT"), vide its Order dated September 7, 2026 in CA (CAA) No. 30/230/HDB/2026 ("NCLT Order"), for the purpose of scrutinizing, in a fair and transparent manner, the remote e-voting process and the e-voting at the Meeting of the Equity Shareholders of Venmax Drugs and Pharmaceuticals Limited ("the Company" / "Transferee Company") held on Saturday, October 24, 2026 at 12:30 P.M. (IST) through VC / OAVM ("the Meeting"), on the following resolution:

   "Approval of the Scheme of Amalgamation of Hatri Pharma Private Limited (Transferor Company) with and into Venmax Drugs and Pharmaceuticals Limited (Transferee Company) and their respective Shareholders and Creditors under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("the Scheme")."

2) The management of the Company is responsible for ensuring compliance with the requirements of the Companies Act, 2013 ("the Act") and the Rules made thereunder, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), the SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 ("SEBI Schemes Master Circular"), the General Circulars issued by the Ministry of Corporate Affairs and the Circular issued by SEBI referred to in the Notice, Secretarial Standard-2 on General Meetings, and the directions contained in the NCLT Order, relating to the conduct of the Meeting and voting by electronic means on the resolution contained in the Notice.

3) My responsibility as the Scrutinizer is restricted to scrutinizing the remote e-voting process and the e-voting at the Meeting in a fair and transparent manner, and to make a

consolidated Scrutinizer's Report of the votes cast "in favour" or "against" the resolution, based on the reports generated from the e-voting system of Central Depository Services (India) Limited ("CDSL") and the records made available to me by the Company and its Registrar and Share Transfer Agent, CIL Securities Limited ("RTA").

4) The Notice dated September 22, 2026 convening the Meeting, together with the Explanatory Statement under Sections 230(3), 232(1) and (2) and 102 of the Act read with Rule 6 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and the enclosures, was sent through electronic mode to the equity shareholders whose e-mail IDs were registered with the RTA / Depositories / Company and whose names appeared in the Register of Members / list of Beneficial Owners as on Friday, September 18, 2026. The Notice was published by way of advertisement in Financial Express (English) and Nava Telangana (Telugu) on September 19, 2026.

5) The voting rights of the equity shareholders were reckoned in proportion to their shareholding in the paid-up equity share capital of the Company as on the cut-off date, i.e. Friday, October 16, 2026. The paid-up equity share capital of the Company as on the cut-off date was 1,15,82,930 equity shares of ₹10 each, held by 6992 equity shareholders.

6) The Company availed the e-voting services of CDSL (EVSN: 261010001). The remote e-voting period commenced on Wednesday, October 21, 2026 at 9:00 A.M. (IST) and ended on Friday, October 23, 2026 at 5:00 P.M. (IST), whereafter the remote e-voting module was disabled by CDSL. All 65 votes cast through remote e-voting were cast within the said period.

7) As per the Venue Attendance Report generated by CDSL, 40 (forty) distinct equity shareholders, all belonging to the public category, attended the Meeting through VC / OAVM. The quorum of 30 (thirty) equity shareholders prescribed under Section 103(1)(a)(iii) of the Act and the NCLT Order was present.

8) The facility of e-voting at the Meeting was made available to the equity shareholders attending the Meeting through VC / OAVM who had not cast their vote through remote e-voting. 8 (eight) equity shareholders, each of whom was present at the Meeting as per the Venue Attendance Report, cast their votes at the Meeting.

9) On comparison of the remote e-voting report with the report of e-voting at the Meeting, no equity shareholder was found to have voted through both modes. Accordingly, no vote was required to be treated as invalid on this account.

10) After the conclusion of e-voting at the Meeting, the votes cast at the Meeting were first counted, and thereafter the votes cast through remote e-voting were unblocked on October 24, 2026 at 1:35 P.M. (IST).

11) As per the records furnished by the Company, Mr. Venkat Narender Nuka (holding 9,26,775 equity shares) is the only member of the Promoter and Promoter Group who voted on the resolution. All other equity shareholders who voted belong to the public category, within the meaning of Rule 2(e) of the Securities Contracts (Regulation) Rules, 1957.

12) There were no invalid votes and no abstentions. Every equity shareholder who voted cast all the votes held by them as on the cut-off date either "in favour" or "against" the resolution.

13) **Result of voting:** The consolidated result of remote e-voting and e-voting at the Meeting on the resolution is as under:

a) **Voted in favour of the resolution**

Mode of voting	Number of members voted	Number of valid votes cast by them	% of total number of valid votes cast
Remote e-voting	64	72,09,365	99.9816
E-voting at the Meeting	8	1,177	0.0163
Total	**72**	**72,10,542**	**99.9979**

b) **Voted against the resolution**

Mode of voting	Number of members voted	Number of valid votes cast by them	% of total number of valid votes cast
Remote e-voting	1	150	0.0021
E-voting at the Meeting	0	0	0.0000
Total	**1**	**150**	**0.0021**

c) **Invalid votes**

Mode of voting	Number of members whose votes were declared invalid	Number of invalid votes
Remote e-voting	0	0
E-voting at the Meeting	0	0
Total	**0**	**0**

d) **Separate result of voting by Public Shareholders (SEBI Schemes Master Circular)**

Particulars	Number of members voted	Number of valid votes cast by them	% of total valid votes cast by Public Shareholders
Votes in favour	71	62,83,767	99.9976
Votes against	1	150	0.0024
Total votes cast by Public Shareholders	**72**	**62,83,917**	**100.0000**

14) The category-wise result in the format prescribed for disclosure of voting results under Regulation 44(3) of the SEBI LODR Regulations is given in Annexure-I, and the summary of voting is given in Annexure-II. The list of equity shareholders who attended the Meeting, the list of equity shareholders who voted through e-voting at the Meeting and the list of equity shareholders who voted through remote e-voting are given in Annexure-III, Annexure-IV and Annexure-V respectively.

15) The resolution has been approved by 72 out of 73 equity shareholders voting (a majority in number), representing 72,10,542 votes out of 72,10,692 valid votes cast, i.e. 99.9979% in value, which is more than three-fourths in value of the equity shareholders voting through remote e-voting and e-voting at the Meeting.

16) The votes cast by the Public Shareholders in favour of the resolution (62,83,767 votes) are more than the votes cast by the Public Shareholders against the resolution (150 votes).

17) Accordingly, the resolution approving the Scheme of Amalgamation of Hatri Pharma Private Limited with and into Venmax Drugs and Pharmaceuticals Limited and their respective Shareholders and Creditors stands **approved with the requisite majority** by the Equity Shareholders of the Company.

18) The electronic data, the reports generated by CDSL and all other relevant records relating to the e-voting shall be handed over to the Chairperson / Company Secretary of the Company for safe keeping.

19) You may accordingly declare the result of the voting. The result, together with this report, may be placed on the website of the Company, displayed at the Registered Office of the Company, and communicated to BSE Limited within the time prescribed under Regulation 44(3) of the SEBI LODR Regulations, i.e. on or before Tuesday, October 27, 2026.

Thanking you,

Yours faithfully,

Kruthi Kalaga
Advocate
Scrutinizer appointed by the Hon'ble NCLT, Hyderabad Bench-II
Place: Hyderabad
Date: October 24, 2026

ANNEXURE-I

Voting results in the format prescribed under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Particulars	Details
Name of the Company	Venmax Drugs and Pharmaceuticals Limited (BSE Scrip Code: 531015; ISIN: INE154G01022)
Type of meeting	Meeting of the Equity Shareholders convened by the Hon'ble NCLT, Hyderabad Bench-II, in CA (CAA) No. 30/230/HDB/ 2026
Date of the meeting	Saturday, October 24, 2026
Cut-off date	Friday, October 16, 2026
ssTotal number of shareholders on the cut-off date	6992
No. of shareholders present in the meeting either in person or through proxy	Not applicable (meeting held through VC / OAVM; facility of proxy not available)
Resolution No. / Description	Approval of the Scheme of Amalgamation of Hatri Pharma Private Limited with and into Venmax Drugs and Pharmaceuticals Limited and their respective Shareholders and Creditors under Sections 230 to 232 of the Companies Act, 2013
Resolution required	Special (majority in number representing three-fourths in value under Section 230(6) of the Act; and votes of Public Shareholders in favour to exceed votes against under the SEBI Schemes Master Circular)
Whether promoter / promoter group are interested in the agenda / resolution	No
Mode of voting	Remote e-voting and e-voting at the Meeting (CDSL)
Whether resolution is passed	Yes, with the requisite majority

ANNEXURE-I

(contd.) – Category-wise voting results on Resolution

Category	Mode of voting	No. of shares held (1)	No. of votes polled (2)	% of votes polled on outstanding shares (3) = [(2)/ (1)] *100	No. of votes – in favour (4)	No. of votes – against (5)	% of votes in favour on votes polled (6) = [(4)/ (2)] *100	% of votes against on votes polled (7) = [(5)/ (2)] *100
Promoter and Promoter Group	Remote e-voting	12,12,025	9,26,775	76.4650	9,26,775	0	100.0000	0.0000
	E-voting at the Meeting		0	0.0000	0	0	0.0000	0.0000
	Total	**12,12,025**	**9,26,775**	**76.4650**	**9,26,775**	**0**	**100.0000**	**0.0000**
Public – Institutions	Remote e-voting	0	0	0.0000	0	0	0.0000	0.0000
	E-voting at the Meeting		0	0.0000	0	0	0.0000	0.0000
	Total	**0**	**0**	**0.0000**	**0**	**0**	**0.0000**	**0.0000**
Public – non-institutions	Remote e-voting	1,03,70,905	62,82,740	60.5804	62,82,590	150	99.9976	0.0024
	E-voting at the Meeting		1,177	0.0113	1,177	0	100.0000	0.0000
	Total	**1,03,70,905**	**62,83,917**	**60.5918**	**62,83,767**	**150**	**99.9976**	**0.0024**
Total Public Shareholders	**Remote e-voting + e-voting at the Meeting**	**1,03,70,905**	**62,83,917**	**60.5918**	**62,83,767**	**150**	**99.9976**	**0.0024**
Grand Total	**Remote e-voting + e-voting at the Meeting**	**1,15,82,930**	**72,10,692**	**62.2527**	**72,10,542**	**150**	**99.9979**	**0.0021**

ANNEXURE-II

M/s VENMAX DRUGS AND PHARMACEUTICALS LIMITED

NCLT CONVENED MEETING OF EQUITY SHAREHOLDERS HELD ON OCTOBER 24, 2026 – SUMMARY OF VOTING

						In Favour			Against			Invalid	
Item No.	**Resolution**	**Type of resolution**	**Mode**	**Number of members voted**	**Total valid votes**	**Number of members voted**	**Number of votes cast by them**	**% of total number of valid votes cast**	**Number of members voted**	**Number of votes cast by them**	**% of total number of valid votes cast**	**Number of members voted**	**Number of votes cast by them**
1	Approval of the Scheme of Amalgamation of Hatri Pharma Private Limited with Venmax Drugs and Pharmaceuticals Limited and their respective shareholders, pursuant to the NCLT Order dated September 7, 2026	Special	Remote e-voting	65	72,09,515	64	72,09,365	99.9816	1	150	0.0021	0	0
			E-voting at the Meeting	8	1,177	8	1,177	0.0163	0	0	0.0000	0	0
			Total	**73**	**72,10,692**	**72**	**72,10,542**	**99.9979**	**1**	**150**	**0.0021**	**0**	**0**